Advances in cervical cancer pharmacotherapies
M Markman - Expert Review of Clinical Pharmacology, 2014 - Taylor & Francis
While widely employed in the management of cervical cancer, the overall utility of systemic
anti-neoplastic agents in this clinical setting is quite modest. Cisplatin, the single most …
anti-neoplastic agents in this clinical setting is quite modest. Cisplatin, the single most …
Advances in cervical cancer pharmacotherapies
M Markman - Expert Review of Clinical Pharmacology, 2014 - search.proquest.com
While widely employed in the management of cervical cancer, the overall utility of systemic
anti-neoplastic agents in this clinical setting is quite modest. Cisplatin, the single most …
anti-neoplastic agents in this clinical setting is quite modest. Cisplatin, the single most …
Advances in cervical cancer pharmacotherapies
M Markman - Expert review of clinical pharmacology, 2014 - pubmed.ncbi.nlm.nih.gov
While widely employed in the management of cervical cancer, the overall utility of systemic
anti-neoplastic agents in this clinical setting is quite modest. Cisplatin, the single most …
anti-neoplastic agents in this clinical setting is quite modest. Cisplatin, the single most …
Advances in cervical cancer pharmacotherapies.
M Markman - Expert Review of Clinical Pharmacology, 2014 - europepmc.org
While widely employed in the management of cervical cancer, the overall utility of systemic
anti-neoplastic agents in this clinical setting is quite modest. Cisplatin, the single most …
anti-neoplastic agents in this clinical setting is quite modest. Cisplatin, the single most …